Metacrine, Inc., established in 2014 and operating from its headquarters in San Diego, California, is a clinical-stage biopharmaceutical company. The firm's core mission involves identifying and advancing novel therapies specifically designed for patients suffering from gastrointestinal disorders. Among its developmental pipeline, Metacrine is progressing MET642, a therapeutic candidate which has successfully completed its Phase I clinical investigation aimed at treating ulcerative colitis.